Cincinnati

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• HIV8 trials
• Asthma7 trials
• Colorectal cancer2 trials
• Liver and biliary tract cancer2 trials
• Lupus (SLE)2 trials
• Melanoma2 trials
• Childhood cancers1 trial
• COPD1 trial
• Endometrial cancer1 trial
• Glioblastoma1 trial
• Head and neck cancer1 trial
• Hodgkin lymphoma1 trial
• and 5 more

Phase

• Phase 315 trials
• Phase 26 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Active, not recruiting16 trials
• Completed7 trials
• Recruiting3 trials

Lead sponsor

• GlaxoSmithKline15 trials
• ViiV Healthcare8 trials
• Tesaro, Inc.3 trials

Running trials

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

  Contact: Carl Fichtenbaum (principal investigator)

• Active, not recruiting

  A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

  NCT07053384· Phase 1· ViiV Healthcare· Source

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

  NCT06741397· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

  NCT06694805· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

  NCT06372496· Phase 4· GlaxoSmithKline· Source

• Recruiting

  A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  NCT05878717· Phase 2/3· GlaxoSmithKline· Source

  Contact: Rachel Foot (principal investigator)

• Active, not recruiting

  A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

  NCT05996471· Phase 2· ViiV Healthcare· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Benjamin Kuritzky (principal investigator)

• Active, not recruiting

  A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

  NCT05757102· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

  NCT04179032· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

  NCT02951052· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• HIV1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

  NCT05274750· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718103· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source

• Completed

  Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

  NCT04133909· Phase 3· GlaxoSmithKline· Source

• Completed

  Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

  NCT01649765· Phase 2· GlaxoSmithKline· Source